Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 6/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32665574 | 0.87 | ALDH1A1 (0.43) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL32665511 | 0.82 | CA12 (0.51) | KMT2AEGFRCA12CA1CA2 | |
| SCHEMBL32665104 | 0.82 | KMT2A (0.56) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL32665599 | 0.78 | CA1 (0.41) | CA12CA1CA2CA9NPC1 | |
| Hydrochloric Acid SCHEMBL32665128 | 0.78 | NPC1 (0.47) | KMT2AEGFRCA2NPC1RAB9A | |
| SCHEMBL32665307 | 0.78 | HDAC1 (0.55) | KMT2ANPC1RAB9APOLBCASP3 | |
| SCHEMBL32665582 | 0.76 | NPSR1 (0.48) | KMT2AEGFRCA1CA2NPC1 | |
| SCHEMBL21334008 | 0.73 | CA2 (0.55) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL32665537 | 0.73 | ALDH1A1 (0.48) | KMT2APOLBALDH1A1 | |
| SCHEMBL25698618 | 0.73 | NPC1 (0.62) | KMT2AEGFRCA2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | KMT2A 4014/4885EGFR 1861/4885CA12 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.